Loading patent…
AssigneeFred Hutchinson Cancer Research Center
InventorsMarie Bleakley, Robson Dossa, Daniel Sommermeyer
Estimating the term…
The present disclosure provides compositions and methods for targeting a minor histocompatibility (H) antigen (HA-1H) to, for example, prevent or manage relapse of a hematological malignancy after allogeneic hematopoietic stem cell transplantation (HCT). Also provided are transgene constructs encoding engineered binding proteins, such as a T cell receptor or a chimeric antigen receptor, optionally encoding additional components such as a co-receptor and/or safety switch. Such transgene constructs can be transduced into an immune cell, such as a T cell, and used as an immunotherapy in a subject having a hematological malignancy or at risk for recurrence of the hematological malignancy (e.g., leukemia, lymphoma, myeloma).
An engineered immune cell, comprising a heterologous polynucleotide encoding a binding protein that includes:
An engineered immune cell, comprising a heterologous transgene polynucleotide comprising or consisting of the nucleotide sequence of SEQ ID NO:
An engineered immune cell, comprising a heterologous polynucleotide encoding a binding protein that includes:
Dependencies are inferred from the claim text.